You can buy or sell Agenus and other stocks, options, ETFs, and crypto commission-free!
Agenus Inc. Common Stock, also called Agenus, is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Read More Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
52 Week High
52 Week Low
The Motley Fool21h
3 Top Growth Stocks to Buy Right Now
Growth stocks are known for their market-beating returns, which also explains why such stocks often command a premium in the stock market.
Seeking AlphaMar 14
Agenus Inc.'s (AGEN) CEO Garo Armen on Q4 2018 Results - Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN) Q4 2018 Results Earnings Conference Call March 14, 2019 8:30 AM ET Company Participants Jennifer Buell - Chief Operating Officer Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Vice President of Clinical Development Christine Klaskin - Vice President of Finance & Principal Accounting Officer Conference Call Participants Matt Phipps - William Blair Operator Good morning ladies and gentlemen. Thank you for standing by and welcome to the Agenus Fourth Quarter...
Yahoo FinanceMar 14
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
Agenus Inc. AGEN announced that it has received $7.5 million in cash as milestone payment from Gilead Sciences GILD after the FDA accepted the company's investigational new drug (IND) application for AGEN1423. AGEN1423 is a first-in-class molecule, currently developed in partnership with Gilead as a potential treatment for cancer. Agenus is also eligible to receive additional milestones from Gilead in 2019 as well as in the future. Shares of Agenus were up almost 3.5% following this news on Wednesday. In ...
-$0.28 per share
-$0.40 per share